A year of profitable growth

In our fourth quarter, we faced challenging market conditions impacting our results negatively. We concluded a year of profitable growth resulting in an expanded EBIT margin of 150 basis point and we delivered a book-to-bill ratio of 1.09 for the full year. At the recent ESTRO exhibition, we successfully launched a new market leading CT-adaptive linac, Elekta Evo, completing our comprehensive product offering.

Gustaf Salford
President and CEO

Fourth quarter

• Gross order intake increased by 1 percent to SEK 6,436 M (6,359), corresponding to a 1 percent decrease in constant exchange rates
• Net sales decreased by 2 percent to SEK 5,023 M (5,125), corresponding to a 2 percent decrease in constant exchange rates
• Adjusted gross margin amounted to 36.6 percent (37.8)
• Adjusted operating income (Adjusted EBIT) amounted to SEK 651 M (832), corresponding to an adjusted EBIT margin of 13.0 percent (16.2)
• Earnings per share was SEK 1.08 (1.43) before dilution and SEK 1.08 (1.43) after dilution
• Adjusted earnings per share was SEK 1.15 (1.53) before dilution and SEK 1.15 (1.53) after dilution
• Cash flow after continuous investments amounted to SEK 872 M (1,574)

Full year

• Gross order intake decreased by 2 percent to SEK 19,697 M (20,143), corresponding to a 5 percent decrease in constant exchange rates
• Net sales increased by 7 percent to SEK 18,119 M (16,869), corresponding to a 5 percent increase in constant exchange rates
• Adjusted gross margin amounted to 37.5 percent (38.1)
• Adjusted operating income (Adjusted EBIT) amounted to SEK 2,145 M (1,743), corresponding to an adjusted EBIT margin of 11.8 percent (10.3)
• Earnings per share was SEK 3.41 (2.47) before dilution and SEK 3.41 (2.47) after dilution
• Adjusted earnings per share was SEK 3.62 (3.11) before dilution and SEK 3.62 (3.10) after dilution
• Cash flow after continuous investments amounted to SEK 815 M (400)
• The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments)

1 Compared to last fiscal year based on constant exchange rates.
2 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 27.
3 Adjusted EBITDA = EBITDA excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 28.
4 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability, see page 28.
5 Adjusted earnings per share = Net income attributable to Parent Company shareholders, excluding items affecting comparability, in relation to the weighted average number of shares (excluding treasury shares), see page 29.

# # #
 
For further information, please contact:
Tobias Hägglöv, CFO
Tel: +46 76 107 4799, e-mail: tobias.hagglov@elekta.com  
Time zone: CET: Central European Time

Peter Nyquist, Head of Investor Relations
Tel: +46 70 575 29 06, e-mail: peter.nyquist@elekta.com
Time zone: CET (Central European Time)

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on “X”, formerly known as Twitter.